MX2021000307A - Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética. - Google Patents
Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética.Info
- Publication number
- MX2021000307A MX2021000307A MX2021000307A MX2021000307A MX2021000307A MX 2021000307 A MX2021000307 A MX 2021000307A MX 2021000307 A MX2021000307 A MX 2021000307A MX 2021000307 A MX2021000307 A MX 2021000307A MX 2021000307 A MX2021000307 A MX 2021000307A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen binding
- binding domain
- engineered
- compositions
- methods related
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Se describen constructos de unión a antígeno-Fc que tienen un dominio de unión a CD38 y dos o más dominios Fc, así como los métodos para usar dichos constructos. También se describen los polipéptidos que forman tales construcciones. Los monómeros de dominio Fc que se incluyen en las construcciones pueden incluir sustituciones de aminoácidos que promueven la homodimerización o heterodimerización.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862696759P | 2018-07-11 | 2018-07-11 | |
US201862733036P | 2018-09-18 | 2018-09-18 | |
US201862744067P | 2018-10-10 | 2018-10-10 | |
PCT/US2019/041468 WO2020014526A2 (en) | 2018-07-11 | 2019-07-11 | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021000307A true MX2021000307A (es) | 2021-09-08 |
Family
ID=69141927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021000307A MX2021000307A (es) | 2018-07-11 | 2019-07-11 | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210269546A1 (es) |
EP (1) | EP3820516A4 (es) |
JP (1) | JP2021530498A (es) |
KR (1) | KR20210044218A (es) |
CN (1) | CN113194990A (es) |
AU (1) | AU2019299973A1 (es) |
BR (1) | BR112021000416A2 (es) |
CA (1) | CA3106142A1 (es) |
IL (1) | IL280046A (es) |
MX (1) | MX2021000307A (es) |
WO (1) | WO2020014526A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
CN115873127A (zh) * | 2021-11-26 | 2023-03-31 | 深圳科兴药业有限公司 | 重组长效人生长激素融合蛋白及其制备方法和用途 |
US20240034808A1 (en) * | 2021-12-17 | 2024-02-01 | Modex Therapeutics, Inc. | Antigen binding polypeptide complexes containing extracellular domains of tnfsf ligands |
TW202334204A (zh) * | 2021-12-21 | 2023-09-01 | 美商莫德斯醫療公司 | 條件性活化之抗原結合多肽複合物及其使用方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140242081A1 (en) * | 2011-07-18 | 2014-08-28 | Micromet Ag | Dosing regimens for treatment of cea-expressing cancers |
JP2015527869A (ja) * | 2011-08-26 | 2015-09-24 | メリマック ファーマシューティカルズ インコーポレーティッド | タンデムFc二重特異性抗体 |
EA201500741A1 (ru) * | 2013-01-10 | 2016-01-29 | Генмаб Б.В. | ВАРИАНТЫ Fc-ОБЛАСТИ IGG1 ЧЕЛОВЕКА И ИХ ПРИМЕНЕНИЕ |
IL307913A (en) * | 2014-12-04 | 2023-12-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of acute myeloid leukemia |
CA2994746A1 (en) * | 2015-08-11 | 2017-02-16 | Cellectis | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
US20220153833A1 (en) * | 2016-03-02 | 2022-05-19 | Momenta Pharmaceuticals, Inc. | METHODS RELATED TO ENGINEERED Fc CONSTRUCTS |
KR102462084B1 (ko) * | 2016-05-23 | 2022-11-02 | 모멘타 파머슈티컬스 인코포레이티드 | 유전자 조작 Fc 작제물에 관한 조성물 및 방법 |
CA3043251A1 (en) * | 2016-12-09 | 2018-06-14 | Gliknik Inc. | Methods of treating inflammatory disorders with multivalent fc compounds |
-
2019
- 2019-07-11 WO PCT/US2019/041468 patent/WO2020014526A2/en unknown
- 2019-07-11 KR KR1020217004249A patent/KR20210044218A/ko unknown
- 2019-07-11 US US17/259,491 patent/US20210269546A1/en not_active Abandoned
- 2019-07-11 CN CN201980059584.0A patent/CN113194990A/zh active Pending
- 2019-07-11 MX MX2021000307A patent/MX2021000307A/es unknown
- 2019-07-11 JP JP2021500858A patent/JP2021530498A/ja not_active Withdrawn
- 2019-07-11 EP EP19833127.4A patent/EP3820516A4/en not_active Withdrawn
- 2019-07-11 BR BR112021000416-5A patent/BR112021000416A2/pt unknown
- 2019-07-11 CA CA3106142A patent/CA3106142A1/en active Pending
- 2019-07-11 AU AU2019299973A patent/AU2019299973A1/en not_active Abandoned
-
2021
- 2021-01-10 IL IL280046A patent/IL280046A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20210269546A1 (en) | 2021-09-02 |
KR20210044218A (ko) | 2021-04-22 |
EP3820516A2 (en) | 2021-05-19 |
BR112021000416A2 (pt) | 2021-04-06 |
WO2020014526A2 (en) | 2020-01-16 |
IL280046A (en) | 2021-03-01 |
CA3106142A1 (en) | 2020-01-16 |
EP3820516A4 (en) | 2022-04-20 |
WO2020014526A3 (en) | 2020-02-20 |
AU2019299973A1 (en) | 2021-02-18 |
JP2021530498A (ja) | 2021-11-11 |
CN113194990A (zh) | 2021-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021000307A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc dirigidos a cd38 diseñados por ingeniería genética. | |
NZ756763A (en) | Engineered transferrin receptor binding polypeptides | |
PH12018500295A1 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
CR20200171A (es) | Contorsbodies 2 + 1 biespecíficos | |
EP4275698A3 (en) | Anti-tigit antibodies and methods of use thereof | |
NZ590668A (en) | TNF-alpha ANTAGONIST MULTI-TARGET BINDING PROTEINS | |
EP4299595A3 (en) | Compositions and methods related to engineered fc constructs | |
WO2018151821A8 (en) | ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF | |
TN2010000169A1 (en) | Molecules and methods for modulating complement component | |
MX2018005399A (es) | Nuevo polipeptido con afinidad por pd-l1. | |
WO2018169922A3 (en) | Chimeric antigen receptors for melanoma and uses thereof | |
MX2023005201A (es) | Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas. | |
PH12019550194A1 (en) | Anti-ceacam1 antibody and use thereof | |
MX2021000290A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente dirigidos a ccr4. | |
MX2021000306A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno y fc modificados genéticamente dirigidos a ctla-4. | |
MX2021000287A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2021000280A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2022003316A (es) | Composiciones y métodos relacionados con constructos de fc-dominio de unión al antígeno diseñados por ingeniería dirigidos a cd38. | |
MX2021000281A (es) | Composiciones y métodos relacionados con construcciones de dominio de unión a antígeno y fc modificadas genéticamente dirigidas a pd-l1. | |
MX2021000288A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2022001882A (es) | Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40. | |
MX2021000305A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
AU2018278809A1 (en) | Recombinant ROBO2 proteins, compositions, methods and uses thereof | |
WO2024064366A3 (en) | Engineered chimeric fusion protein compositions and methods of use thereof | |
EA202190831A2 (ru) | Химерный полипептидный комплекс и способы его получения и применения |